Rani Bansal
Medical Oncology · Raleigh, NCNPI 1306208467
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,180 of the $2,807 with a category attached, or 77.7%. Gilead accounts for 85.2% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $2,398, more than ten times the $99 reported in 2021.
Across 7 payments — averaging $400.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Eisai Inc.$125
- E.r. Squibb & Sons, L.L.C.$125
- Incyte Corporation$99
- Genentech USA, Inc.$68
Across 15 payments — averaging $27,430 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$145K
- AstraZeneca$138K
- Genentech, Inc.$80K
- Jazz Pharmaceuticals Inc.$49K
What the payments were for
- Consulting fees$2,18078%
- Food & beverage$52819%
- Education$994%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 3 | $2,390 |
| Eisai Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Incyte Corporation | 1 | $99 |
| Genentech USA, Inc. | 1 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,807 in reported general payments places this provider in the 60th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 43 | $557,484 |
| IbrancePalbociclib | 12 | $187,953 |
| Anastrozole | 206 | $3,250 |
| Letrozole | 36 | $803 |
| Dexamethasone | 18 | $394 |
| Tamoxifen Citrate | 18 | $243 |
| Prochlorperazine Maleate | 31 | $228 |
| Ondansetron Hcl | 36 | $171 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Raleigh
- Thomas LeblancDurham$1.7M
- David RizzieriCharlotte$714K
- Raghava InduruAlbemarle$625K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Thomas StinchcombeChapel Hill$281K
- Steven SorscherWinston Salem$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.